Page last updated: 2024-10-26

etidronate and Osteoarthritis of Knee

etidronate has been researched along with Osteoarthritis of Knee in 11 studies

Etidronic Acid: A diphosphonate which affects calcium metabolism. It inhibits ectopic calcification and slows down bone resorption and bone turnover.
etidronic acid : A 1,1-bis(phosphonic acid) that is (ethane-1,1-diyl)bis(phosphonic acid) having a hydroxy substituent at the 1-position. It inhibits the formation, growth, and dissolution of hydroxyapatite crystals by chemisorption to calcium phosphate surfaces.

Research Excerpts

ExcerptRelevanceReference
"To evaluate the frequency of upper gastrointestinal (GI) tract adverse events associated with risedronate during two (2-year) randomized, double-blind, parallel-group, placebo-controlled studies."2.71Upper gastrointestinal tract safety of daily oral risedronate in patients taking NSAIDs: a randomized, double-blind, placebo-controlled trial. ( Adami, S; Barton, IP; Bensen, WG; Cline, GA; Cohen, SB; Hosterman, MA; Pavelka, K, 2005)
"Alendronate treatment reduced bony osteophyte development."1.36In vivo microfocal computed tomography and micro-magnetic resonance imaging evaluation of antiresorptive and antiinflammatory drugs as preventive treatments of osteoarthritis in the rat. ( Doschak, MR; Jones, MD; Li, G; Maksymowych, WP; Tran, CW; Zernicke, RF, 2010)

Research

Studies (11)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's8 (72.73)29.6817
2010's3 (27.27)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Iwamoto, J1
Takeda, T1
Sato, Y1
Matsumoto, H1
Jones, MD1
Tran, CW1
Li, G1
Maksymowych, WP1
Zernicke, RF1
Doschak, MR1
Bartlett, SJ1
Ling, SM1
Mayo, NE1
Scott, SC1
Bingham, CO4
Spector, TD2
Conaghan, PG2
Buckland-Wright, JC3
Garnero, P3
Cline, GA5
Beary, JF4
Valent, DJ1
Meyer, JM4
Adami, S2
Pavelka, K1
Hosterman, MA1
Barton, IP1
Cohen, SB3
Bensen, WG1
Messent, EA1
Ward, RJ1
Tonkin, C1
Dougados, M1
Clauw, DJ1
Pelletier, JP2
Raynauld, JP2
Strand, V1
Simon, LS1
Martel-Pelletier, J1
Berthiaume, MJ1
Abram, F1
Choquette, D1
Haraoui, B1
Aronstein, WS1
Christiansen, C1
Fujita, T1
Fujii, Y1
Okada, SF1
Miyauchi, A1
Takagi, Y1

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Altering Bone Microarchitecture and Mechanics by Off-label Pharmaceutical Intervention[NCT05204836]Phase 156 participants (Anticipated)Interventional2023-05-16Recruiting
A Randomized Placebo Controlled Trial Testing The Effect of Zoledronic Acid on Hip Osteoarthritis[NCT04303026]Phase 370 participants (Anticipated)Interventional2020-03-02Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

1 review available for etidronate and Osteoarthritis of Knee

ArticleYear
Effects of risedronate on osteoarthritis of the knee.
    Yonsei medical journal, 2010, Volume: 51, Issue:2

    Topics: Animals; Calcium Channel Blockers; Cartilage; Diphosphonates; Etidronic Acid; Humans; Osteoarthritis

2010

Trials

7 trials available for etidronate and Osteoarthritis of Knee

ArticleYear
Identifying common trajectories of joint space narrowing over two years in knee osteoarthritis.
    Arthritis care & research, 2011, Volume: 63, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Disability Evaluation; Disease Pro

2011
Effect of risedronate on joint structure and symptoms of knee osteoarthritis: results of the BRISK randomized, controlled trial [ISRCTN01928173].
    Arthritis research & therapy, 2005, Volume: 7, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Double-Blind Method; Etidronic Acid; Female; Humans; Knee Joint; Mal

2005
Upper gastrointestinal tract safety of daily oral risedronate in patients taking NSAIDs: a randomized, double-blind, placebo-controlled trial.
    Mayo Clinic proceedings, 2005, Volume: 80, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Calcium Channel Blockers; D

2005
A 2 yr longitudinal radiographic study examining the effect of a bisphosphonate (risedronate) upon subchondral bone loss in osteoarthritic knee patients.
    Rheumatology (Oxford, England), 2007, Volume: 46, Issue:2

    Topics: Adult; Aged; Bone Density Conservation Agents; Disease Progression; Dose-Response Relationship, Drug

2007
Risedronate decreases biochemical markers of cartilage degradation but does not decrease symptoms or slow radiographic progression in patients with medial compartment osteoarthritis of the knee: results of the two-year multinational knee osteoarthritis st
    Arthritis and rheumatism, 2006, Volume: 54, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Bone Density Conservation Agents; Cartilage; Disease Pro

2006
Risedronate decreases biochemical markers of cartilage degradation but does not decrease symptoms or slow radiographic progression in patients with medial compartment osteoarthritis of the knee: results of the two-year multinational knee osteoarthritis st
    Arthritis and rheumatism, 2006, Volume: 54, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Bone Density Conservation Agents; Cartilage; Disease Pro

2006
Risedronate decreases biochemical markers of cartilage degradation but does not decrease symptoms or slow radiographic progression in patients with medial compartment osteoarthritis of the knee: results of the two-year multinational knee osteoarthritis st
    Arthritis and rheumatism, 2006, Volume: 54, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Bone Density Conservation Agents; Cartilage; Disease Pro

2006
Risedronate decreases biochemical markers of cartilage degradation but does not decrease symptoms or slow radiographic progression in patients with medial compartment osteoarthritis of the knee: results of the two-year multinational knee osteoarthritis st
    Arthritis and rheumatism, 2006, Volume: 54, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Bone Density Conservation Agents; Cartilage; Disease Pro

2006
Relationships between biochemical markers of bone and cartilage degradation with radiological progression in patients with knee osteoarthritis receiving risedronate: the Knee Osteoarthritis Structural Arthritis randomized clinical trial.
    Osteoarthritis and cartilage, 2008, Volume: 16, Issue:6

    Topics: Aged; Biomarkers; Bone Density Conservation Agents; Bone Resorption; Cartilage, Articular; Collagen

2008
Analgesic effect of etidronate on degenerative joint disease.
    Journal of bone and mineral metabolism, 2001, Volume: 19, Issue:4

    Topics: Aged; Analgesics, Non-Narcotic; Back Pain; Bone Density; Dose-Response Relationship, Drug; Etidronic

2001

Other Studies

3 other studies available for etidronate and Osteoarthritis of Knee

ArticleYear
In vivo microfocal computed tomography and micro-magnetic resonance imaging evaluation of antiresorptive and antiinflammatory drugs as preventive treatments of osteoarthritis in the rat.
    Arthritis and rheumatism, 2010, Volume: 62, Issue:9

    Topics: Alendronate; Animals; Anti-Inflammatory Agents, Non-Steroidal; Bone Density Conservation Agents; Dis

2010
Osteoporosis drug may protect joints.
    Health news (Waltham, Mass.), 2006, Volume: 12, Issue:3

    Topics: Bone Density Conservation Agents; Etidronic Acid; Humans; Osteoarthritis, Knee; Risedronic Acid

2006
Correlation between bone lesion changes and cartilage volume loss in patients with osteoarthritis of the knee as assessed by quantitative magnetic resonance imaging over a 24-month period.
    Annals of the rheumatic diseases, 2008, Volume: 67, Issue:5

    Topics: Analysis of Variance; Bone and Bones; Bone Cysts; Cartilage, Articular; Diphosphonates; Disease Prog

2008